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INTRODUCTION
Americans spend a large amount of money on the purchase of
prescription drugs. Under Medicare’s prescription drug benefit
(Medicare Part D), Medicare beneficiaries must pay $4,050 out
of pocket, not including monthly premiums averaging around
$30/month (from Medicare Prescription Drug Plan Finder
website), before entering the catastrophic coverage range, after
which they are responsible for just 5% of drug costs. Within
the infamous doughnut hole between $2,510 and $4,050,
beneficiaries will pay 100% of the cost of their prescription
drugs. Small wonder, then, that patients, and the physicians
caring for them, are grateful for access to free drug samples.
These samples can enable therapeutic trials of necessary
drugs, avoiding the expense of paying for a full course of a
drug that might have to be discarded after the first dose leads
to a side effect. A frequent justification provided by physicians
is that use of free samples provides access to necessary drugs
for patients who could not otherwise afford them.
1–4
Unfortunately, these “free” samples do have a cost. Strong
evidence links use of samples to suboptimal drug choice.
5,6
Substantial administrative overhead is required to maintain an
orderly sample cabinet and to ensure that only up-to-date
drugs are dispensed with appropriate written instructions.
3,7
Since many offices fail to invest in oversight of the sample
cabinet, it is likely that many patients receive drugs with
inadequate information regarding dosing schedule, side effects,
and potential drug interactions. And these samples come with
an expectation of access to physician and staff time by sales
representatives for the companies that supply the drugs.
Thus, it is not surprising that policy analysts are examining
whether the costs of having access to these samples outweigh
their putative benefits. Questions regarding use of free pre-
scription drug samples have been added to some of the most
useful survey databases, including the Medicare Current
Beneficiary Survey (MCBS) and the Medical Expenditure Panel
Survey (MEPS). These surveys can be used to generate
estimates applicable to the overall US population and many
important subgroups. Research using these data has begun to
be published, including an analysis of 2004 data from the
MCBS by Tija et al. in the present issue of the Journal.
8
Elsewhere, Cutrona et al.
9 and Alexander et al.
10 have
presented results based on 2004 data from the MEPS.
Together, these studies give an important window to the
epidemiology of free sample use, which previously has been
described only in limited populations.
The study by Tjia et al. is an important contribution.
First, it focuses on the Medicare population. The frequency
of chronic disease in older individuals makes them particu-
larly vulnerable to medication costs.
11 These individuals may
also be more susceptible to the type of drug-adverse effects
that provide one rationale for using free samples to initiate a
new course of therapy. Moreover, this type of research has
great policy relevance, since the structure of this federal
program can be modified, either administratively or legisla-
tively, in response to new research information. Since the
question was put in place in 2004, changes in sample use
following the advent of Medicare Part D in 2006 can be
examined. Second, the MCBS and MEPS use a different
question to determine whether or not a patient has received
free samples. Whereas the MEPS asks respondents about
sample receipt during a roughly 4-month period, the MCBS
asks respondents whether they have “… ever, sometimes or
never asked for or received free samples from your doctor…”
While both surveys have detailed demographic information,
the MCBS also asks about cost–related nonadherence to
medications, a behavior that health-care providers presum-
ably hope to minimize with samples.
The work of Tjia et al. confirms other analyses that have
shown that samples are not targeted to people with lower
income. Indeed, there is actually an inverse relationship
between income and likelihood of accessing free samples,
although this gradient is not significant after adjusting for
other demographic data, having a pharmacy benefit, and
comorbidity. Non-Hispanic Whites are more likely to access
free samples than other racial and ethnic groups, a pattern
that is reminiscent of other disparities in health-care situa-
tions requiring subjective judgments. However, the fact that
free samples are not well targeted does not mean that they are
not an important source of drugs for persons with limited
resources–it simply means that many samples go to persons
who have adequate resources.
Other studies, by Cutrona et al. and Alexander et al., come
to similar conclusions regarding patterns of use: free samples
are not targeted to those in greatest need. Cutrona concludes
that this lack of targeting confirms that free samples serve “as
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890a marketing tool, not as a safety net.” While samples may be
part of a marketing plan, we believe these surveys do not
permit such clear conclusions. Indeed, Alexander et al.’s
examination of prescription expenditures during the periods
before and after drug sampling is consistent with the idea that
these samples are disproportionately used by patients who
have increasing drug expenditures. Again, it is not possible to
determine if the sampling causes the increased drug costs by
inducing use of excessively costly drugs or is a response to that
increased burden. In Alexander's analysis, the vast majority of
persons who received a sample drug did not in fact fill a
prescription for that drug during the months following the
sample.
An important new finding from Tjia's study is the strong
association between accessing free samples and cost-related
medication nonadherence (CRN). This finding will likely be
interpreted to indicate that samples are being used to avoid
this reason for nonadherence. However, as the authors note, it
is also plausible that the use of free samples either causes, or
is at least symptomatic of, the use of expensive drugs when
less expensive ones would be as effective. Thus, the use of free
samples may cause the CRN, rather than attenuate it.
How should physicians, health-care organizations, and
policy makers react to these data? It is clear that they do
not give a definitive answer regarding the question of
whether the benefits of having a free sample cabinet
outweigh the costs. However, just as one cannot wait for
definitive randomized trials when treating medical illnesses,
evidence-based practice dictates that decisions should be
made with the data at hand. These decisions should give
great weight to the systematic evidence that samples induce
the use of expensive drugs when less expensive ones would
work as well or better. They should consider the acknowl-
edged dangers of dispensing drugs without appropriate
labeling regarding dosing and appropriate counseling re-
garding specifics of use and potential side effects.
It seems clear that in some cases, particularly in large
organizations such as many academic primary care practices,
the sample process should be eliminated or at least extensively
reworked. Many health-care organizations have taken this
bold step, and we applaud them. We believe this action
provides important benefits to trainees, encouraging the use
of evidence-based medication choices rather than simply
selecting from what is available in the sample cabinet today
and role modeling a healthy separation of clinical practice and
pharmaceutical sales representatives. Moreover, these large
organizations can systematize the process of using the patient
assistance programs provided by most pharmaceutical com-
panies to assist those patients whose needs cannot be met by
their income or insurance coverage.
Smaller practices may find it harder to abandon the sample
cabinet. In addition to the (debatable) benefits for patients
unable to purchase medications, the convenience of being able
to initiate drug therapy without an immediate trip to the
pharmacy is likely valued by many patients.
12 If there is no
compelling evidence that the use of free samples is bad
medicine, then the lure of getting quick and “free” treatment
may be a competitive advantage for those physicians who
choose to continue to use samples. There is good anecdotal
evidence for this; indeed a recent AARP Bulletin article
13
advises that if drug costs remain high despite part D, one
might “… try asking your doctor for free samples.” However,
any practice that elects to use samples should institute a
formal plan for their management, including appropriate
written instructions for use, checking for expiration dates
and drug interactions prior to dispensing, and counseling of
the patient regarding potential side effects. Most importantly,
the physician should not let the samples available dictate what
is prescribed. The presence of free samples must not interfere
with the practice of evidence-based medicine.
On a policy level, it is appropriate to seek additional data.
Although descriptive epidemiology of the type presented by Tjia
et al is essential, it does not answer questions about the net
and individual effects of using drug samples. This will require
patient level data regarding the appropriateness and cost of
the drug sampled versus alternatives, physician and patient
motives for sample use, and potential and actual adverse
effects of such dispensing. This type of detailed observational
study may be more useful and feasible than randomized trials,
which would identify net benefits, but might not capture either
individual patients who benefit from the samples or system
level harms. This is a non-trivial issue-the pharmaceutical
industry provides $16 billion in free samples per year, as noted
by Tjia et al. The evidence that this expense improves health-
care processes or outcomes is currently limited to anecdote.
Indeed, these dollars may well discourage the use of evidence-
based medicine.
If, however, there are many individual patients who
benefit from the free sample system, even while it increases
overall medical costs and discourages evidence-based prac-
tice, then new approaches should seek to preserve these
benefits while addressing the harms. Since it seems unlikely
that the goal of universal affordable access to needed
pharmaceuticals will be met anytime soon, partial solutions
should not be shunned. Some authors have advocated the
substitution of free vouchers that would allow free samples
to be dispensed with the same pharmacist oversight that
paid prescriptions receive.
7 The pharmaceutical industry has
developed formal Pharmacy Assistance Programs that pro-
vide drugs worth billions of dollars to persons with limited
resources (www.pparx.org). If technology can allow these
programs to be as accessible as an unlocked, poorly
organized sample closet, we may be able to improve both
access to drugs and evidence-based prescribing.
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